





ما
امید
رازتنه
نگه میداریم
Hope Alive





About Sobhan Oncology

Sobhan Oncology Pharmaceutical company is one of the most advanced pharmaceutical companies in Iran and in the Middle East. The company's main goal is to produce best-quality anti-cancer pharmaceutical products in the global range, by using an advanced and intelligent management under the supervision of experienced specialists and highest level of technical knowledge in accordance with the latest pharmaceutical standards, in order to increase the accessibility of all patients to up to date treatments.

Sobhan Oncology is always mentioned as one of the leading companies in producing high-quality drugs for the Iranian and regional markets. Benefited from the experiences of world-renowned companies and in the meanwhile cooperating with reputable pharmaceutical companies such as Sanofi of France and Roche of Switzerland, Sobhan Oncology company has established the first production line of specialized injectable oncology drugs in Iran by using the latest machines and technology of the world, and presents manufactured licensed pharmaceutical products with international standards and reasonable prices, to the country's market and also international markets.


Having more than 200 employees and 100 pharmaceutical products, this company has succeeded to be the largest and most reliable pharmaceutical company in producing and supplying oncology drugs, in the field of cancer treatment in Iran and in the Middle East and far east.

From the past to the present

As the first company producing specialized cancer drugs in the Middle East, Sobhan Oncology Pharmaceutical Company was established in 2002 and was put into operation in 2007. The executive operation of this national project started on a land of 25000 square meters in the industrial city of Rasht under the supervision of the German LSMW company, one of the pioneers in this field. All production lines and processes in this pharmaceutical site are in full compliance with GMP standards.

In 2009, The company succeeded to produce and introduce the products of the world's most reputable companies, such as Roche and Stragen of Switzerland, Sanofi of France, Ebewe of Austria, Biosyn of Germany and Cipla of India, into the country's pharmaceutical market.

In 2011 through it's experienced specialists, Sobhan Oncology managed to use nanotechnology in producing and supplying Liposomal Doxorubicin. Taking this action, Sobhan Oncology claimed the title of the second pharmaceutical company in the world after the United states, in producing and supplying Liposomal Doxorubicin in cooperation with an Iranian knowledge-based company.





For the future

Sobhan Oncology company hopes to achieve an elevated position in the pharmaceutical industry of the Middle East region, by ever-increasing the expertise level of its scientific and technical staff and employees' collective efforts, in order to continuously improve the quality and variety of its drugs. Maintenance, promotion and constant and knowledge-oriented development of the quality, is one of the visions of Sobhan Oncology.

Supplying patient's demanding medicines at a reasonable price, obtaining the continuous satisfaction of the therapeutic community (patients), and improving the quality of life and the health of the society has always been the epigraph of the company's actions.

One of the most important goals of Sobhan Oncology company is to plan on developing the variety of manufactured drugs based on the needs of pharmaceutical market of Iran and countries of the region, in order to increase the export of high-quality pharmaceutical products to other countries.

Our responsibility

The mission and scope of the activities in Sobhan Oncology Pharmaceutical Company, as one of the most advanced companies producing Oncology drugs in the Middle East, is including research and development in the field of producing and supplying pharmaceutical products using advanced technology and smart management, in order to increase all patient's accessibility to up to date treatments and improve the quality of their life. In this regard, Sobhan Oncology commits itself to scientific promotion of it's human capital and preserving resources of all stakeholders to help create a healthier society.

In pharmaceutical industry, Sobhan Oncology produces and distributes high-quality pharmaceutical products based on the real needs of the Iranian society. This company operates on the basis of respecting the rights of all beneficiary groups, including patients and doctors, and also cooperating with the most reliable active companies in the pharmaceutical industry of the world. It also uses qualified human forces, advanced technologies and machines, while respecting human and moral values, in the direction of growth and sustainable development.

Establishing an environmental focus and attitude in Sobhan Oncology Pharmaceutical Company, has led this company to be always obligated to comply with all standards of protecting environment side by side with using the most advanced facilities and systems in the world, along with producing the safest and most effective specialized anti-cancer products. By complying with all international principles and standards of environmental protection, this company is continuously attempting to take continuous and effective steps in protecting the environment as the safest industry in the country.

Compliance with all the principles and rules of drug manufacturing in this company, is validated by the world's most prestigious pharmaceutical companies such as Roche and Sanofi. Possessing all necessary facilities to analyzing cytotoxic substances and isolator along with allocated protective covers, provides all the necessary conditions for activity of personnel engaged with toxic substances. This important factor is the unique feature of the quality control laboratories of this collection, and has provided necessary potential for implementing and complying with all control standards of anticancer drugs in the country.

Production lines and capacity

Sobhan Oncology company is the only pharmaceutical company possessing all production lines of specialized Oncology drugs in Iran, which is capable of producing drugs in a wide range of forms including: tablets, capsules, soluble vials and lyophilized vials with a capacity of about eleven million tablets and capsules and one million vials for a working shift per year.



Sobhan Oncology business partners

By obtaining technical knowledge from its international partners such as Roche and Stragen of Switzerland, Sanofi of France, Biosyn of Germany, Cipla of India and Nipponkayaco of Japan, Sobhan Oncology Company has been able to produce high quality drugs in such a way that the high consumption volume of these drugs and success in supplying and continuous consumption of manufactured products, is the proof of the provided quality.

In the field of supplying pharmaceutical raw materials, Sobhan Oncology Company is always attempting to use the best available sources, and in the meantime of providing the required raw materials from the mentioned business partners, it cooperates with reliable European companies that produce raw materials.

- Sanofi - France
- Stragen - switzerland
- Ofichem - Netherlands
- Synbias Pharma -switzerland
- Naprod life - India
- Cipla - India
- Pellets Pharma - India
- Biosyn - German



- Heraeus - Germany
- BDR - India
- Jiangsu Hengrui - China
- Jiangsu Hansoh - China
- Nipponkayaco - Japan
- Roche - Swiss
- Ebewe - Austria

Heraeus



HANSOH PHARMA



NIPPON KAYAKU



Roche



Ebewe PHARMA



International Markets:


Following the successful launch of its products in the Iranian market, Sobhan Oncology has paved the way for entering international markets. The company has already exported its products to several countries such as Syria, Iraq, and Uganda, and has signed cooperation agreements with Vietnam, the Philippines, Sudan, and Cameroon. In addition, Sobhan Oncology is actively pursuing product registration in other countries including Kazakhstan, Sri Lanka, Tajikistan, Russia, and Belarus.

Currently, the company has over 100 pharmaceutical dossiers under registration in various regions worldwide, targeting

- Middle East: Syria, Iraq, Oman, Jordan, Yemen, Lebanon
- Far East: The Philippines, Sri Lanka, Vietnam
- CIS Region: Tajikistan, Russia, Belarus
- Africa: Uganda, Kenya (East Africa), Senegal, Cameroon (West Africa)
- Latin America: Nicaragua, Venezuela, Bolivia

The Export Department of Sobhan Oncology is committed to offering its high-quality products to international markets and expanding its global presence.

We keep hope alive.





Certificates, Approvals, and Achieved Standards

- GMP Certificate | Solid Dosage Forms Production Line
- GMP Certificate | Sterile Production Line
- Accredited Laboratory Certificate
- ISO 9001 Certificate (Quality Management System)
- ISO 14001 Certificate (Environmental Management System)
- ISO 45001 Certificate (Occupational Health and Safety Management System)
- ISO 10004 Certificate (Customer Satisfaction Management System)
- ISO 10002 Certificate (Customer Complaint Handling Management System)
- ISO 10015 Certificate (Competence and Personnel Development Management System)
- ISO 30401 Certificate (Knowledge Management System)
- HSE-MS Certificate (Health, Safety, and Environment Management System)
- Quality Commitment Certificate for the Production Quality Management of Paclitaxel from the Iranian Food and Drug Administration
- QC and QA Approvals from Roche, Switzerland for the analysis of Xeloda and Copegus products
- QC and QA Approvals from Sanofi Aventis, Switzerland for Taxotere 20 mg and Taxotere 80 mg products
- Selected as the Top Company in 2016 for Consumer Rights Protection and recipient of the International Quality Award from BID Institute







 **Sobhan**
Oncology



SOBOTAXEL®

Generic name: PACLITAXEL

Dosage form: Concentrate for solution for infusion

Strength: 30mg/5ml, 100mg/16.7ml, 150mg/25ml,
300mg/50ml

Indication: Non-Small Cell Lung Cancer (NSCLC)

Ovarian Cancer, Breast Cancer, AIDS-related Kaposi's
Sarcoma



SOBELVIN®

Generic name: VINORELBINE

Dosage form: Concentrate for solution for infusion

Strength: 10mg/ml, 50mg/5ml

Indication: Non-Small Cell Lung Cancer (NSCLC)



ELSOTER®

Generic name: DOCETAXEL

Dosage form: Concentrate for solution for infusion

Strength: 20mg/1ml, 80mg/4ml, 160mg/8ml

Indication: Non-small Cell Lung Cancer (NSCLC)
Breast Cancer, Gastric Cancer, Head & Neck Cancer, Prostate
Cancer



CISPLAT®

Generic name: CISPLATIN

Dosage form: Concentrate for Solution for Infusion

Strength: 10mg/20ml, 50mg/50ml

Indication: Testicular cancer, Lung cancer, Cervical cancer, Bladder cancer, Head and neck cancer, and Ovarian cancer



CARBOPLAT®

Generic name: CARBOPLATIN

Dosage form: Concentrate for Solution for Infusion

Strength: 50mg/5ml, 150mg/15ml, 450mg/45ml

Indication: Ovarian cancer, Small cell lung cancer, Seminoma testicular germ cell tumors



XOPLAT®

Generic name: OXALIPLATIN

Dosage form: Concentrate for Solution for Infusion

Strength: 50mg/10ml, 100mg/20ml

Indication: Colorectal Cancer



BORUNOZ®

Generic name: BORTEZOMIB
Dosage form: Lyophilized powder
Strength: 3.5mg per vial
Indication: Mantle Cell Lymphoma/
Multiple Myeloma



GEMSIBAN®

Generic name: GEMCITABINE
Dosage form: Concentrate for solution for
infusion - Lyophilized powder
Strength: 200mg/2ml, 1000mg/10ml - 200mg and
1000mg per vial
Indication: Non-Small Cell Lung Cancer
(NSCLC), Pancreatic Cancer,
Breast Cancer, Ovarian
Cancer



Zoledronic Acid

Dosage form: Concentrate for solution for infusion -
Lyophilized powder
Strength: 4mg/5ml - 4mg per vial
Indication: Prevention of skeletal related events in
advanced malignancies involving bone, Tumor-
induced hypercalcemia, Paget's disease of bone,
Osteoporosis in men and postmenopausal
women



PEMEXED®

Generic name: PEMETREXED
Dosage form: Lyophilized powder
Strength: 100mg, 500mg
Indication: Non-Small Cell Lung Cancer (NSCLC),
Mesothelioma



CAMSOBAN®

Generic name: IRINOTECAN

Dosage form: Concentrate for Solution for Infusion

Strength: 40mg/2ml, 100mg/5ml, 300mg/15ml

Indication: Metastatic Colorectal Cancer (CRC), adenocarcinoma of the pancreas



EPIRUBIN®

Generic name: EPIRUBICIN

Dosage form: Concentrate for Solution for Infusion

Strength: 10mg/5ml, 50mg/25ml

Indication: Breast carcinoma, Ovarian cancer, Gastric cancer, Small cell lung cancer



ADRIABIN®

Generic name: DOXORUBICIN

Dosage form: Concentrate for solution for infusion

Strength: 10mg/5ml, 50mg/25ml

Indication: Acute leukemias, Hodgkin's lymphoma, non-Hodgkin's lymphoma, some solid tumors including breast cancer, advanced soft-tissue sarcoma, Bladder tumors



PLERIXAFOR

Generic name: PLERIXAFOR

Dosage form: Solution for subcutaneous injection

Strength: 24mg/1.2ml

Indication: Hematopoietic stem cell mobilization in lymphoma or multiple myeloma



BENETRA®

Generic name: BENDAMUSTINE

Dosage form: Lyophilized Powder

Strength: 25mg, 100mg

Indication: Chronic Lymphocytic Leukemia(CLL),
Multiple myeloma



SUNITIBAN®

Generic name: SUNITINIB

Dosage form: Capsule

Strength: 12.5mg, 25mg, 50mg

Indication: Gastrointestinal Stromal Tumor,
Renal Cell Carcinoma, Pancreatic Neuro-
endocrine Tumors



SOTAMIDE®

Generic name: FLUTAMIDE

Dosage form: Tablet

Strength: 250mg

Indication: Prostatic carcinoma



TARSOBAN®

Generic name: ERLOTINIB

Dosage form: Film-coated tablet

Strength: 100mg, 150mg

Indication: Non-Small Cell Lung Cancer (NSCLC),
Pancreatic Cancer



RADOTEM®

Generic name: TEMOZOLOMIDE

Dosage form: Capsule

Strength: 20mg, 100mg, 140mg, 180mg, 250mg

Indication: Anaplastic Astrocytoma, Glioblastoma
Multiforme



ONCOCAP®

Generic name: CAPECITABINE

Dosage form: Film-coated tablet

Strength: 500mg

Indication: Colorectal cancer, Gastric cancer, Breast
cancer



IMATIB®

Generic name: IMATINIB
Dosage form: Capsule

Strength: 100mg

Indication: Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (Ph-positive ALL), Myelodysplastic/myeloproliferative diseases (MDS/MPD), Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) -Gastrointestinal stromal tumors (GIST) - Dermatofibrosarcoma protuberans (DFSP)



NILOTA®

Generic name: NILOTINIB
Dosage form: Capsule

Strength: 150mg, 200mg

Indication: Philadelphia chromosome-positive chronic myeloid leukemia (CML)



LENASOB®

Generic name: LENALIDOMIDE
Dosage form: Capsule

Strength: 5mg, 10mg, 15mg, 25mg

Indication: Myelodysplastic Syndromes/ Multiple Myeloma/ Mantle Cell Lymphoma/ Follicular Lymphoma



BICALUMID®

Generic name: BICALUTAMIDE
Dosage form: Film-coated tablet

Strength: 50mg, 150mg

Indication: Metastatic Prostate Cancer



POMALIDOMIDE

Generic name: POMALIDOMIDE

Dosage form: Capsule

Strength: 1mg, 2mg, 3mg, 4mg

Indication: Multiple Myeloma



SOBRUVICA®

Generic name: IBRUTINIB

Dosage form: Capsule

Strength: 70mg, 140mg

Indication: Chronic lymphocytic leukemia, Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, Marginal Zone Lymphoma



SOBRANCE®

Generic name: PALBOCICLIB

Dosage form: Capsule

Strength: 75mg, 100mg, 125mg

Indication: Breast Cancer



ABIRATERONE

Generic name: ABIRATERONE

Dosage form: Tablet

Strength: 250mg, 500mg

Indication: Metastatic castration-resistant prostate cancer (CRPC)



NEXOBAN®

Generic name: SORAFENIB

Dosage form: Film-coated tablet

Strength: 200mg

Indication: Renal cell carcinoma (RCC), Thyroid carcinoma, Hepatocellular carcinoma



SOVINUS®

Generic name: EVEROLIMUS

Dosage form: Tablet

Strength: 5mg, 10mg

Indication: Breast Cancer, Renal Cell Carcinoma, Advanced Neuroendocrine Tumors, Renal Angiomyolipoma, Subependymal Giant Cell Astrocytoma



REGRASOB®

Generic name: REGORAFENIB

Dosage form: Film-coated tablet

Strength: 40mg

Indication: Colorectal Cancer, Gastrointestinal Stromal Tumors, Hepatocellular Carcinoma



OLASOB®

Generic Name: OLAPARIB

Dosage form: Film-coated tablet

Strength: 100mg, 150mg

Indication: Ovarian cancer, Fallopian tube cancer, Peritoneal cancer, Chronic myeloid leukemia, Breast cancer, Pancreatic cancer, Prostate cancer



XTALOSOB®

Generic Name: ENZALUTAMIDE

Dosage form: Film-coated tablet

Strength: 40mg, 80mg

Indication: Castration-resistant Metastatic Prostate Cancer



TAGSIMER®

Generic Name: OSIMERTINIB

Dosage form: Film-coated tablet

Strength: 40mg, 80mg

Indication: Metastatic Non-Small Cell Lung Cancer (NSCLC)



GEFITIB®

Generic name: GEFITINIB

Dosage form: Film-coated tablet

Strength: 250mg

Indication: Locally advanced or metastatic non-small cell lung cancer



MACITENTAN

Generic name: MACITENTAN

Dosage form: Film-coated tablet

Strength: 10mg

Indication: Pulmonary arterial hypertension (PAH)



XELOCAP®

Generic Name: CAPECITABINE

Dosage form: Film-coated tablet

Strength: 500mg

Indication: Colorectal cancer, Gastric cancer, Breast cancer



GIOSOB®

Generic name: TERIFLUNOMIDE

Dosage form: Film-coated tablet

Strength: 7mg, 14mg

Indication: Multiple Sclerosis



FINGOLIMOD

Generic name: FINGOLIMOD

Dosage form: Capsule

Strength: 0.5mg

Indication: Multiple Sclerosis



Pyralock®

Generic name: FAMPRIDINE

Dosage form: Extended-release tablet

Strength: 10mg

Indication: Multiple Sclerosis



EVINOS®

Generic name: EVEROLIMUS

Dosage form: Tablet

Strength: 0/25mg, 0/75mg

Indication: Liver transplantation, Renal transplantation



BARISOB®

Generic name: BARICITINIB

Dosage form: Film-coated tablet

Strength: 2mg, 4mg

Indication: Rheumatoid Arthritis, Atopic Dermatitis, COVID-19



TOFACITINIB

Generic name: TOFACITINIB

Dosage form: Film-coated tablet

Strength: 5mg, 10mg

Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis



CASPOFUNGIN

Generic Name: CASPOFUNGIN

Dosage form: Lyophilized powder

Strength: 50mg, 70mg

Indication: Invasive Aspergillosis, Invasive Candidiasis

POMALIDOMIDE

Generic name: POMALIDOMIDE
Dosage form: Capsule
Strength: 1mg, 2mg, 3mg, 4mg
Indication: Multiple Myeloma

ZALOSOB

Generic name: OXALIPLATIN
Dosage form: Concentrate for Solution for Infusion
Strength: 50mg/10ml, 100mg/20ml
Indication: Colorectal Cancer

REGORAFENIB

Generic name: REGORAFENIB
Dosage form: Film-coated tablet
Strength: 40mg
Indication: Colorectal Cancer, Gastrointestinal Stromal Tumors, Hepatocellular Carcinoma

BARICITINIB

Generic name: BARICITINIB
Dosage form: Film-coated tablet
Strength: 2mg, 4mg
Indication: Rheumatoid Arthritis, Atopic Dermatitis, COVID-19

IBRUTINIB

Generic name: IBRUTINIB
Dosage form: Capsule
Strength: 70mg, 140mg
Indication: Chronic lymphocytic leukemia, Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, Marginal Zone Lymphoma

2024
1403

CARBOPLAT
INJECTION

ZOLEDRONIC
ACID
INJECTION

OSIMERTINIB
TABLET

OLAPARIB
TABLET

ELSOTERE
INJECTION

ABIRATRONE
TABLET

SUNITIBAN
CAPSULE

EPIRUBIN
INJECTION

GEFITIB
TABLET


MACITENRAN
TABLET

OZANIMOD
TABLET

GEMCITABINE
LYOPHILIZED
POWDER

PLERIXAFOR
INJECTION

2025
1404



2016
1395

- ▶ SOBRUVICA CAPSULE
- ▶ BICALUMID TABLET
- ▶ BARISOB TABLET
- ▶ IMAKIN TABLET

2018
1397

- ▶ DIMETHYL FUMARATE CAPSULE
- ▶ GEMSIBAN INJECTION
- ▶ ENZALUTAMIDE TABLET

2020
1399

- ▶ NEXOBAN TABLET
- ▶ LENASOB CAPSULE
- ▶ FAMPRIDINE TABLET
- ▶ SOBRANCE CAPSULE
- ▶ RADOTEM CAPSULE
- ▶ EVINOS TABLET

2019
1398

- ▶ REMDESIVIR INJECTION

2025
1404

- ▶ GEMCITABINE LYOPHILIZED POWDER
- ▶ MACITENTAN TABLET
- ▶ PLERIXAFOR INJECTION
- ▶ GEFITIB TABLET
- ▶ OZANIMOD TABLET

we keep hope alive →





Keeping **مَا**
امید **Hope** **Alive** **رازندہ**
نگه میداریم



Head Office:

No. 8 , 23rd Alley, Hasan Nasrollah (Vozara) Street, Tehran- IRAN

Tel: +02188549881

Postal Code: 1513933714

Fax: +98 21 88549883

Production Plant:

Gilan, Rasht, Rasht Industrial City, San'at 2 Boulevard, 3rd Street

Tel: +98 13 3188 2241-2

Fax: +981331883058

Sobhanoncology.com
Info@sobhanoncology.com
Sobhan-oncology-pharmaceutical
S o b h a n _ o n c o l o g y